Latest News
EU Market Entry for Non-EU Pharma & Biotech Companies: Complete Regulatory Guide
EU Market Entry for Non-EU Pharma & Biotech Companies: Complete Regulatory Guide
Entering the European Union pharmaceutical market requires more than regulatory awareness; it demands a coordinated approach to compliance, legal structuring, and quality system implementation. For non-EU pharmaceutical and biotech companies, the transition from clinical development to EU commercialisation involves alignment with European Medicines Agency (EMA) expectations, the establishment of an EU-based legal presence, and the implementation of systems that meet EU Good Manufacturing Practice (GMP) standards.
This guide provides a practical, end-to-end overview of the regulatory framework, operational requirements, timelines, and common risks associated with EU market entry. We have also put together a handy checklist which you can download here.
Prefer to watch? Listen to our EU market entry podcast discussion
In this Pharma Conversations episode, Charley Maxwell of Orion GXP Consulting discusses practical considerations for pharmaceutical and biotech companies planning market entry into Europe, including regulatory strategy, supply chain readiness, Annex 21, importation and QP certification.
What Are the Regulatory Requirements for Entering the EU Market?
To place a medicinal product on the EU market, a company must obtain a Marketing Authorisation through either the EMA centralised procedure or via national competent authorities, depending on the product type. This authorisation is only one component of a broader compliance framework. The organisation must also ensure that all manufacturing activities align with EU GMP as defined in EudraLex Volume 4, and that a compliant Quality Management System is fully operational.
In addition, non-EU companies are required to establish a legal presence within the EU or partner with an organisation that can fulfil this role. A Qualified Person must be appointed to take legal responsibility for certifying that each batch released to the market meets both GMP requirements and the conditions of the Marketing Authorisation. These obligations apply irrespective of where the product is manufactured, making early alignment with EU expectations essential.
Do You Need an EU Legal Entity or MAH?
A Marketing Authorisation Holder must be established within the EU or European Economic Area, and this entity carries full legal responsibility for the product once it is placed on the market. In practice, non-EU companies typically choose between establishing their own EU-based subsidiary, partnering with a third-party MAH provider, or adopting a virtual operating model that allows them to maintain flexibility while meeting regulatory requirements.
The MAH is accountable for regulatory submissions, ongoing compliance, pharmacovigilance systems, and lifecycle management of the product. Misalignment or ambiguity in this structure is one of the most common early-stage risks, often leading to delays or complications later in the approval process.
What Is an MIA and When Is It Required?
A Manufacturer’s or Importer’s Authorisation is required when medicinal products are imported into the EU from a third country. This authorisation ensures that the organisation responsible for importation operates in full compliance with EU GMP and has the necessary systems, facilities, and personnel in place to manage these activities.
For non-EU companies, this requirement is typically addressed either through a partnership with an EU-based MIA holder (such as Orion GXP Consulting) or by establishing an authorised entity within the EU. The scope of the MIA must align precisely with the activities being performed, particularly where batch certification and release are involved.
How Does QP Certification and Batch Release Work?
Every medicinal product released to the EU market must undergo certification by a Qualified Person, in accordance with EU GMP Annex 16. This process is a legal requirement and represents a critical control point in the supply chain. The QP must confirm that each batch has been manufactured and tested in compliance with GMP, that it meets the specifications defined in the Marketing Authorisation, and that all relevant documentation has been reviewed and approved.
For products manufactured outside the EU, additional controls apply. These may include re-testing within the EU and a more detailed verification of supply chain integrity. In many cases, the availability and oversight capacity of the QP can become a limiting factor in timelines, particularly where systems and documentation are not fully aligned.
What GMP Standards Apply?
Compliance with EU GMP is fundamental to market entry and extends across all aspects of manufacturing, testing, and quality oversight. EudraLex Volume 4 provides the core framework, supported by specific annexes that define expectations in key areas. Annex 11, for example, addresses computerised systems and data integrity, requiring organisations to demonstrate control over electronic records and validation processes. Annex 16 governs the certification and release of batches by a Qualified Person, setting out detailed requirements for oversight and documentation.
In practice, regulators expect to see validated processes, robust documentation, clear traceability, and a Quality Management System that is both comprehensive and inspection-ready. Deficiencies in these areas are among the most common causes of delay or regulatory challenge.
What Inspections Should You Expect?
Regulatory inspections are an integral part of the EU market entry process and may be conducted by national competent authorities such as the HPRA or MHRA, as well as by the EMA in the context of centralised procedures. These inspections assess compliance with GMP, the effectiveness of the Quality Management System, and the integrity of data and documentation across the organisation.
Importantly, inspection scope is not limited to EU-based operations. Manufacturing sites located outside the EU may also be inspected if they form part of the supply chain. As a result, inspection readiness must be approached as a global requirement, with consistent standards applied across all sites and partners.
Typical Timelines for EU Market Entry
The timeline for EU market entry varies depending on the maturity of the organisation and the complexity of the product, but a structured pathway typically unfolds over a period of twelve to eighteen months. Early stages focus on establishing the legal and regulatory framework, including the MAH structure and overall strategy. This is followed by the implementation or refinement of the Quality Management System, supplier qualification, and preparation for audit and inspection.
The final phase involves regulatory submission and review, during which the quality of documentation and the completeness of supporting systems become critical. Delays are most often associated with gaps in QMS implementation, deficiencies in supplier oversight, or questions raised during the review process.
Common Failure Points and Delays
In practice, the challenges associated with EU market entry are rarely due to a single issue. More often, delays arise from a combination of factors, including incomplete Quality Management Systems, unclear allocation of responsibilities within the MAH structure, and insufficient attention to supplier qualification and audit readiness. Data integrity issues, particularly those linked to Annex 11 requirements, are another frequent source of regulatory concern.
Organisations that underestimate the importance of Qualified Person oversight or fail to align documentation with regulatory expectations often encounter avoidable delays, increased costs, and additional scrutiny during review.
How to Prepare for an EMA Submission
Preparation for an EMA submission requires a high degree of coordination across regulatory, quality, and operational functions. A complete Common Technical Document must be compiled, supported by validated manufacturing processes and a fully operational Quality Management System. Pharmacovigilance systems must also be in place and aligned with EU requirements.
Effective preparation typically includes a detailed gap analysis against EU standards, followed by targeted remediation and, where appropriate, mock inspections or audit simulations. Early alignment between teams ensures that potential issues are identified and addressed before submission, reducing the risk of delays during the review process.
How Orion GXP Supports EU Market Entry
Orion GXP works with non-EU pharmaceutical and biotech companies to establish a structured and compliant pathway into the European market. This includes the development of regulatory strategy, the establishment of MAH and MIA frameworks, and the implementation of Quality Management Systems aligned with EU GMP requirements. Support also extends to supplier qualification, audit readiness, and preparation for regulatory inspection.
By integrating regulatory, quality, and operational expertise, Orion GXP enables organisations to move efficiently from late-stage development to EU commercialisation while maintaining full compliance with applicable standards.
Key Questions Answered
What is required for a non-EU company to sell medicines in Europe?
A non-EU company must obtain a Marketing Authorisation, establish an EU-based MAH, comply with EU GMP requirements, and ensure that all product batches are certified by a Qualified Person prior to release.
Do I need a Qualified Person (QP)?
Yes. EU regulations require that every batch released to the market is certified by a Qualified Person in accordance with Annex 16.
How long does EU market entry take?
Most organisations should plan for a timeline of twelve to eighteen months, depending on their level of readiness and the complexity of their product.
What is the biggest risk in EU market entry?
The most common risks include incomplete Quality Management Systems, data integrity deficiencies, and lack of clarity in regulatory responsibilities, all of which can lead to delays and additional regulatory scrutiny.
Next Steps
EU market entry is a structured but demanding process that requires early planning, regulatory alignment, and operational discipline. Organisations that succeed are those that integrate compliance into their development strategy from the outset, rather than treating it as a final-stage requirement.
A well-designed regulatory and quality framework not only facilitates approval but also supports long-term success in the European market.
💊 If you require support with importation or commercial batch certification, or if you are looking for QP or RP services, please contact:
📩 admin@oriongxp.com | 🌠www.oriongxp.com
